Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:DOCS NASDAQ:GEN NASDAQ:SLP On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeDOCSDoximity$20.00+3.1%$23.38$17.15▼$76.51$3.58B1.365.51 million shs3.48 million shsGENGen Digital$24.82-0.1%$20.45$17.78▼$32.22$15.05B1.18.62 million shs5.73 million shsSLPSimulations Plus$15.37+1.7%$13.46$11.09▼$34.01$305.30M1.28369,113 shs171,303 shs7 Stocks That Will Be Magnificent in 2026Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceDOCSDoximity+3.03%+5.65%-17.45%-21.80%-60.20%GENGen Digital-0.12%+5.84%+24.16%+11.05%-10.07%SLPSimulations Plus+1.72%+15.22%+1.18%+31.82%-51.51%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeDOCSDoximity$20.00+3.1%$23.38$17.15▼$76.51$3.58B1.365.51 million shs3.48 million shsGENGen Digital$24.82-0.1%$20.45$17.78▼$32.22$15.05B1.18.62 million shs5.73 million shsSLPSimulations Plus$15.37+1.7%$13.46$11.09▼$34.01$305.30M1.28369,113 shs171,303 shs7 Stocks That Will Be Magnificent in 2026Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceDOCSDoximity+3.03%+5.65%-17.45%-21.80%-60.20%GENGen Digital-0.12%+5.84%+24.16%+11.05%-10.07%SLPSimulations Plus+1.72%+15.22%+1.18%+31.82%-51.51%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceDOCSDoximity 2.43Hold$30.6253.13% UpsideGENGen Digital 2.22Hold$31.2926.05% UpsideSLPSimulations Plus 2.20Hold$24.4058.75% UpsideCurrent Analyst Ratings BreakdownLatest SLP, VTY, DOCS, and GEN Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/21/2026SLPSimulations Plus Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D) ➝ Sell (D-)5/15/2026DOCSDoximity Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold (C-) ➝ Sell (D+)5/14/2026DOCSDoximity BarclaysSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOverweight ➝ Equal Weight$38.00 ➝ $20.005/14/2026DOCSDoximity Canaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$34.00 ➝ $30.005/14/2026DOCSDoximity The Goldman Sachs GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetNeutral$28.00 ➝ $24.005/14/2026DOCSDoximity Morgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOverweight$49.00 ➝ $35.005/14/2026DOCSDoximity Leerink PartnersSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOutperform$31.00 ➝ $25.005/14/2026DOCSDoximity BTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy ➝ Neutral5/14/2026DOCSDoximity Wells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOverweight ➝ Equal Weight$32.00 ➝ $18.005/14/2026DOCSDoximity Jefferies Financial GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy ➝ Hold$51.00 ➝ $19.005/14/2026DOCSDoximity Robert W. BairdSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform ➝ Neutral$40.00 ➝ $18.00(Data available from 5/23/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookDOCSDoximity$644.86M5.73$1.27 per share15.78$5.15 per share3.88GENGen Digital$5B3.01$3.04 per share8.16$4.31 per share5.76SLPSimulations Plus$79.18M3.92$1.46 per share10.56$6.20 per share2.48Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateDOCSDoximity$196.05M$0.9920.2015.382.5230.40%20.40%17.43%N/AGENGen Digital$973M$1.5815.718.41N/A19.46%55.47%8.49%8/6/2026 (Estimated)SLPSimulations Plus-$64.72M-$3.13N/A16.18N/A-77.96%16.21%15.00%7/13/2026 (Estimated)Latest SLP, VTY, DOCS, and GEN EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/7/2026Q4 2026GENGen Digital$0.65$0.67+$0.02$0.84$1.25 billion$1.28 billion4/9/2026Q2 2026SLPSimulations Plus$0.27$0.35+$0.08$0.48$21.66 million$24.29 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthDOCSDoximityN/AN/AN/AN/AN/AGENGen Digital$0.502.01%N/A31.65%N/ASLPSimulations PlusN/AN/A-100.00%N/AN/ALatest SLP, VTY, DOCS, and GEN DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date5/7/2026GENGen Digitalquarterly$0.12502.05%5/18/20265/18/20266/10/2026(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioDOCSDoximityN/A6.096.63GENGen Digital3.070.400.47SLPSimulations PlusN/A5.475.47Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipDOCSDoximity87.19%GENGen Digital81.38%SLPSimulations Plus78.08%Insider OwnershipCompanyInsider OwnershipDOCSDoximity31.30%GENGen Digital9.30%SLPSimulations Plus19.10%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableDOCSDoximity890184.71 million126.90 millionN/AGENGen Digital3,500605.66 million549.34 millionOptionableSLPSimulations Plus16020.20 million16.35 millionOptionableSLP, VTY, DOCS, and GEN HeadlinesRecent News About These CompaniesSimulations Plus, Inc. (NASDAQ:SLP) Receives Average Recommendation of "Hold" from BrokeragesMay 22 at 2:14 AM | americanbankingnews.comSimulations Plus to Participate in the 23rd Annual Craig-Hallum Institutional Investor ConferenceMay 21 at 4:05 PM | businesswire.comSimulations Plus (NASDAQ:SLP) Raised to "Buy" at Wall Street ZenMay 16, 2026 | americanbankingnews.comNicholas Company Inc. Buys 78,854 Shares of Simulations Plus, Inc. $SLPMay 11, 2026 | marketbeat.comSimulations Plus (NASDAQ:SLP) Stock Price Crosses Above Two Hundred Day Moving Average - Here's What HappenedMay 7, 2026 | marketbeat.comSimulations Plus and NVIDIA Collaborate to Scale GPU-Accelerated, AI-Assisted Modeling WorkflowsMay 6, 2026 | businesswire.comDo options traders know something about Simulations Plus stock we don't?May 4, 2026 | msn.comCadence Q1 Earnings Top Estimates, 2026 Revenue Outlook RaisedApril 28, 2026 | zacks.comSimulations Plus, Inc. (NASDAQ:SLP) Receives Consensus Rating of "Hold" from BrokeragesApril 27, 2026 | marketbeat.comSimulations Plus Announces Collaboration with Lonza and U.S. FDA to Advance Predictive Frameworks for Complex Oral Drug ProductsApril 21, 2026 | businesswire.comHere’s Simulations Plus Inc (SLP)’s Vision for AI in Drug DevelopmentApril 21, 2026 | finance.yahoo.comSimulations Plus Expands Global Access to Model-Informed Drug Development Training Through Its 2026 Spring SchoolApril 20, 2026 | businesswire.comInsider Selling: Simulations Plus (NASDAQ:SLP) CRO Sells 1,000 Shares of StockApril 17, 2026 | insidertrades.comSimulations Plus: Better Quarter, Same DoubtsApril 15, 2026 | seekingalpha.comSimulations Plus: Down Substantially, Not An Automatic BuyApril 12, 2026 | seekingalpha.comSimulations Plus, Inc. (NASDAQ: SLP) Q2 2026 earnings call transcriptApril 11, 2026 | msn.comSimulations Plus, Inc. (NASDAQ:SLP) Q2 2026 Earnings Call TranscriptApril 11, 2026 | insidermonkey.comWhat's going on with Simulations Plus stock Friday?April 10, 2026 | msn.comSimulations Plus (SLP) Q2 2026 Earnings TranscriptApril 10, 2026 | finance.yahoo.comSimulations (NASDAQ:SLP) Tracks Strong Results In Nasdaq Index ActivityApril 10, 2026 | kalkinemedia.comKSimulations Plus Q2 Earnings & Revenues Beat, Jump Y/Y, Shares SoarApril 10, 2026 | zacks.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeSLP, VTY, DOCS, and GEN Company DescriptionsDoximity NYSE:DOCS$20.00 +0.61 (+3.12%) Closing price 05/22/2026 03:59 PM EasternExtended Trading$19.89 -0.10 (-0.51%) As of 05/22/2026 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Doximity, Inc. operates a cloud-based digital platform for medical professionals in the United States. The company's cloud-based platform provides its members with tools built for medical professionals, enabling them to collaborate with their colleagues, coordinate patient care, conduct virtual patient visits, stay up-to-date with the latest medical news and research, and manage their careers. It primarily serves pharmaceutical companies and health systems. The company was formerly known as 3MD Communications, Inc. and changed its name to Doximity, Inc. in June 2010. Doximity, Inc. was incorporated in 2010 and is headquartered in San Francisco, California.Gen Digital NASDAQ:GEN$24.82 -0.03 (-0.12%) Closing price 05/22/2026 04:00 PM EasternExtended Trading$24.84 +0.02 (+0.08%) As of 05/22/2026 07:49 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Gen Digital Inc. engages in the provision of cyber safety solutions for consumers in the United States, Canada, Latin America, Europe, the Middle East, Africa, the Asia Pacific, and Japan. The company offers security and performance products under Norton, Avast, Avira, AVG, and CCleaner brands that provide real-time protection and maintenance for PCs, Macs, and mobile devices against malware, viruses, adware, and other online threats. It also provides identity protection solutions, including LifeLock Identity Theft Protection, Avast and AVG Secure Identity, Norton Identity Theft Protection, and Dark Web Monitoring for monitoring of credit reports, financial accounts, the dark web, and social media accounts to help safeguard customers' personal information. In addition, the company offers Virtual Private Network (VPN) solutions under Norton, Avast and AVG brands to enhance security and online privacy that allows customers to securely transmit and access private information, such as passwords, bank details, and credit card numbers, when using public Wi-Fi on PCs, Macs, and mobile iOS and Android devices; AntiTrack and Secure Browser products which helps to keep personal information and browsing activity anonymous while browsing online; and Privacy Monitor Assistant and BreachGuard products for removing customers' data from public data broker sites; and ReputationDefender, a white glove service that helps customers manage all aspects of their personal branding online, including search results, social media sites, and overall web presence. It markets and sells its products and related services through retailers, telecom service providers, hardware original equipment manufacturers, and employee benefit providers, as well as e-commerce platform. The company was formerly known as NortonLifeLock Inc. and changed its name to Gen Digital Inc. in November 2022. Gen Digital Inc. was founded in 1982 and is headquartered in Tempe, Arizona.Simulations Plus NASDAQ:SLP$15.37 +0.26 (+1.72%) Closing price 05/22/2026 04:00 PM EasternExtended Trading$15.37 0.00 (0.00%) As of 05/22/2026 06:43 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Simulations Plus, Inc. develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. The company operates through two segments, Software and Services. It offers GastroPlus, which simulates the absorption and drug interaction of compounds administered to humans and animals; and DDDPlus and MembranePlus simulation products. The company also provides products based on mechanistic and mathematical models, such as DILIsym, NAFLDsym, ILDsym, RENAsym, IPFsym, and MITOsym products. In addition, it offers Absorption, Distribution, Metabolism, Excretion, and Toxicity Predictor for chemistry-based computer program that takes molecular structures as inputs and predicts their properties; and MedChem Designer, as well as MonolixSuite products for modeling and simulation that allows for population analyses, rapid clinical trial data analyses, and regulatory submissions. Further, the company provides clinical-pharmacology-based consulting services, which includes population pharmacokinetic and pharmacodynamic modeling, exposure-response analyses, clinical trial simulations, data programming, and technical writing services in support of regulatory submissions; and early drug discovery services. Additionally, it offers creative and insightful consulting services to support its quantitative systems pharmacology/quantitative systems toxicology modelling. The company serves pharmaceutical, biotechnology, agrochemical, cosmetics, and food industry companies, as well as academic and regulatory agencies. Simulations Plus, Inc. was incorporated in 1996 and is headquartered in Lancaster, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 05/18 - 05/22 Was Decker’s Double Beat a Bullish Signal—Or Mere HOKA’s-Pocus? Workday Validates AI Flywheel: Stock Price Recovery Begins SpaceX IPO: Opportunity? Or the Ultimate Hype Trade? Overextended, e.l.f. Beauty Is Primed to Rebound in Back Half Deere Beats Q2 Estimates, But Ag Weakness Weighs on Outlook NVIDIA Price Pullback? Don’t Count on It, Business Is Accelerating Meta Platforms 10% Layoff Raises a Bigger Question About AI Spending Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
